Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Vanda Pharmaceuticals Inc.

www.vandapharma.com

Latest From Vanda Pharmaceuticals Inc.

Bookmark
  • News

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

By Michael Cipriano, Bridget Silverman and Brenda Sandburg
The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review
Bookmark
  • Analysis

Vanda Not Ready To Give Up On Jet Lag Indication For Hetlioz Despite CRL

By Joseph Haas

Complete response letter follows July deficiencies letter that made approval seem highly unlikely. Vanda called the setback perplexing and said it plans to continue working to get jet lag disorder added to the Hetlioz label.

Commercial Life Cycle Management
Bookmark
  • News

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

By Michael Cipriano

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review
Bookmark
  • Analysis

AbbVie And Allergan: Five Big Review Questions To Worry About

By Bridget Silverman

Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.

Drug Review M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vanda Pharmaceuticals Inc.
  • Senior Management
  • Mihael H Polymeropoulos, MD, Pres. & CEO
    James Kelly, EVP, CFO & Treasurer
    Gunther Birznieks, SVP, Bus. Dev.
    Deepak Phadke, PhD, VP, Manufacturing
    Gian Piero Reverberi, SVP, Chief Commercial Officer
  • Contact Info
  • Vanda Pharmaceuticals Inc.
    Phone: (202) 734-3400
    2200 Pennsylvania Ave. NW
    Ste. 300E
    Washington, DC 20037
    USA
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By